RenovoRx (RNXT) Projected to Post Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 14th. Analysts expect RenovoRx to post earnings of ($0.08) per share and revenue of $0.25 million for the quarter.

RenovoRx (NASDAQ:RNXT) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.23 million. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Trading Down 2.2%

Shares of RNXT opened at $1.12 on Tuesday. The company has a market capitalization of $40.78 million, a PE ratio of -2.79 and a beta of 1.26. RenovoRx has a 12 month low of $0.75 and a 12 month high of $1.69. The stock’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.15.

Insider Buying and Selling at RenovoRx

In other RenovoRx news, insider Ramtin Agah acquired 21,000 shares of the stock in a transaction dated Thursday, June 5th. The stock was purchased at an average cost of $1.40 per share, with a total value of $29,400.00. Following the transaction, the insider owned 734,460 shares in the company, valued at approximately $1,028,244. The trade was a 2.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.13% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in RenovoRx stock. Geode Capital Management LLC lifted its holdings in RenovoRx, Inc. (NASDAQ:RNXT) by 9.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 353,603 shares of the company’s stock after acquiring an additional 31,730 shares during the period. Geode Capital Management LLC owned approximately 0.97% of RenovoRx worth $467,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of RenovoRx in a report on Monday, May 19th. Wall Street Zen downgraded RenovoRx from a “hold” rating to a “sell” rating in a report on Saturday, August 2nd. Finally, Ascendiant Capital Markets lifted their price objective on RenovoRx from $11.00 to $11.50 and gave the stock a “buy” rating in a research report on Thursday, June 5th.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.